Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.38
-0.1100-4.42%
Pre-market: 2.400.0200+0.84%06:34 EDT
Volume:11.24M
Turnover:27.01M
Market Cap:861.21M
PE:-1.93
High:2.48
Open:2.48
Low:2.34
Close:2.49
52wk High:12.51
52wk Low:1.64
Shares:361.85M
Float Shares:280.00M
Volume Ratio:1.23
T/O Rate:4.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2321
EPS(LYR):-1.2839
ROE:-53.16%
ROA:-27.42%
PB:1.23
PE(LYR):-1.85

Loading ...

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire
·
Aug 29

Iovance Biotherapeutics Signs $350 Million At-the-Market Offering Agreement with Jefferies LLC

Reuters
·
Aug 23

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 23

Iovance Biotherapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 19

Iovance Biotherapeutics Shares Rise After Receiving Canadian Approval for Skin Cancer Treatment

Dow Jones
·
Aug 19

Iovance Says Amtagvi Gets Health Canada Clearance for Advanced Melanoma

MT Newswires Live
·
Aug 19

BRIEF-Iovance’s Amtagvi Receives Health Canada Approval for Advanced Melanoma

Reuters
·
Aug 19

Iovance Biotherapeutics Files Initial Statement of Beneficial Ownership for New CFO Corleen Roche

Reuters
·
Aug 09

Iovance Biotherapeutics Shares Fall 25% Premarket After Q2 Revenue Miss, Wider Loss

THOMSON REUTERS
·
Aug 08

Stock Track | Iovance Biotherapeutics Plunges 28% Pre-Market on Q2 Miss, Restructuring, and EU Setback

Stock Track
·
Aug 08

Stock Track | Iovance Biotherapeutics Plummets 29% on Q2 Earnings Miss, Restructuring, and EU Setback

Stock Track
·
Aug 08

BUZZ-Iovance falls after Q2 revenue miss, wider loss

Reuters
·
Aug 08

Stock Track | Iovance Biotherapeutics Plunges 28.79% After-Hours on Q2 Earnings Miss and Restructuring Announcement

Stock Track
·
Aug 08

Iovance Biotherapeutics Q2 EPS USD -0.33

THOMSON REUTERS
·
Aug 08

Iovance Biotherapeutics Q2 EPS $(0.33) Misses $(0.29) Estimate, Sales $59.952M Miss $69.792M Estimate

Benzinga
·
Aug 08

Iovance Biotherapeutics Inc - Strategic Restructuring Extends Cash Runway Into 4Q26

THOMSON REUTERS
·
Aug 08

Iovance Biotherapeutics Inc - Reiterates FY25 Revenue Guidance of $250M-$300M

THOMSON REUTERS
·
Aug 08

Iovance Biotherapeutics Inc: Expects Continued Growth in Total Product Revenue for Full Year 2026

THOMSON REUTERS
·
Aug 08

Iovance Biotherapeutics Inc - Strategic Restructuring to Save Over $100 Mln Annually

THOMSON REUTERS
·
Aug 08

Iovance Biotherapeutics Inc - Announces Workforce Reduction of About 19% in 3Q25

THOMSON REUTERS
·
Aug 08